Triazines are an important class of six-membered aromatic heterocycles with three nitrogen atoms that give rise to three regioisomers: 1,2,4-triazines, 1,2,3-triazines, and 1,3, 5-triazine. 1,2,3-Triazines show remarkable reactivity and have attracted attention for their medicinal value. Triazine compounds fused with other carbon and heterocycles are stable and have a broad spectrum of pharmacological activities.
Mineralys Therapeutics announced that the first subject has been dosed in the Launch-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to prescribed background treatment. Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled and resistant hypertension and CKD. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Search 
+86 21 5895 0110 
